Wells Fargo
JANX icon

Wells Fargo’s Janux Therapeutics JANX Stock Holding History

Wells Fargo’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$346K Sell
24,880
-23,039
-48% -$316K ﹤0.01% 4352
2025
Q4 		$661K Buy
47,919
+19,401
+68% +$456K ﹤0.01% 4269
2025
Q3 		$697K Buy
28,518
+4,835
+20% +$118K ﹤0.01% 4067
2025
Q2 		$547K Buy
23,683
+8,338
+54% +$220K ﹤0.01% 4078
2025
Q1 		$414K Buy
15,345
+2,094
+16% +$78.9K ﹤0.01% 4228
2024
Q4 		$709K Buy
13,251
+4,585
+53% +$243K ﹤0.01% 3948
2024
Q3 		$394K Sell
8,666
-341
-4% -$14.8K ﹤0.01% 4146
2024
Q2 		$377K Buy
9,007
+2,907
+48% +$136K ﹤0.01% 4089
2024
Q1 		$230K Buy
6,100
+812
+15% +$17.7K ﹤0.01% 4386
2023
Q4 		$56.7K Buy
5,288
+1,023
+24% +$8.85K ﹤0.01% 5224
2023
Q3 		$43K Sell
4,265
-2,368
-36% -$27.3K ﹤0.01% 5258
2023
Q2 		$78.7K Buy
6,633
+3,548
+115% +$47.4K ﹤0.01% 5178
2023
Q1 		$37.3K Buy
+3,085
New +$51.3K ﹤0.01% 5322
2022
Q4 		– Sell
-45
Closed -$1K – 7594
2022
Q3 		$1K Sell
45
-29,595
-100% -$395K ﹤0.01% 6370
2022
Q2 		$362K Buy
29,640
+24,898
+525% +$295K ﹤0.01% 3941
2022
Q1 		$68K Sell
4,742
-3,481
-42% -$57K ﹤0.01% 5512
2021
Q4 		$163K Buy
8,223
+8,149
+11,012% +$171K ﹤0.01% 5381
2021
Q3 		$2K Buy
+74
New +$2.13K ﹤0.01% 6574

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Wells Fargo's JANX Position: Q1 2026 in Review

Wells Fargo reduced its Janux Therapeutics (JANX) stake by 48% in Q1 2026, selling an estimated $316K and leaving 24,880 shares worth $346K. The position accounts for ﹤0.01% of the portfolio, ranked #4352.

Wells Fargo first reported a position in JANX in Q3 2021 and has held it in 18 quarters since. The position peaked at $709K in Q4 2024. 190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

  • Wells Fargo held 24,880 shares of Janux Therapeutics worth $346K as of Q1 2026.
  • Wells Fargo sold 23,039 Janux Therapeutics shares in Q1 2026, an estimated $316K.
  • Janux Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #4352 holding.
  • Wells Fargo first reported a position in Janux Therapeutics in Q3 2021 and has held it in 18 quarters since.
  • Wells Fargo's Janux Therapeutics position peaked at $709K in Q4 2024.
  • 190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.